Adam joins NDORMS at the University of Oxford on January 1st 2027, from the University of Birmingham, where he is Professor of Translational Rheumatology, Head of the Department of Inflammation and Ageing, Versus Arthritis Chair of Rheumatology and Director of the new £50 million MRC CoRE in Restorative Immunology. His research focuses on understanding the mechanisms that drive inflammation and the development of new treatments for patients with autoimmune rheumatic and chronic inflammatory diseases. He is particularly known for his work on the role of fibroblasts in inflammatory arthritis and the development of therapies that target these cells. Alongside his research, Adam is a practising rheumatologist with clinical expertise in early and treatment-resistant inflammatory arthritis.
As Norman Collisson Professor, Adam will provide leadership in academic rheumatology, with a particular focus on translational research and inflammatory arthritis. He will work across the University and NHS to strengthen Oxford’s translational rheumatology research programme and develop collaborations within NDORMS, the wider Medical Sciences Division and with national and international partners.
A key part of the role will be translating new discoveries into early phase and late phase trials by working across the Botnar and Kennedy Institutes. Adam will also be working in the Oxford University Hospitals NHS Foundation Trust to support the early inflammatory arthritis service.
Professor Jonathan Rees, Head of NDORMS and Director of the Botnar Institute for Musculoskeletal Sciences, said: ‘I am delighted to welcome Adam to the department. This is a key strategic appointment for NDORMS, the University and rheumatology healthcare nationally. Adam brings significant expertise and leadership as highlighted by the recent launch of the new MRC CoRE in Restorative Immunology for which he is the Director. His appointment coupled with the existing expertise and resources available in our Institutes will provide him the opportunity to make a major patient and societal impact in the future. I am so pleased he has agreed to join our NDORMS team.’
Adam said: ‘I'm honoured to take up the Norman Collison Professorship at such a pivotal moment for rheumatology research. Advances in precision medicine, biomarkers, artificial intelligence and targeted therapies mean we are now moving beyond simply managing disease towards earlier diagnosis, personalised treatment, disease prevention and, ultimately, the possibility of cure. This position provides a unique platform to translate these scientific advances into real-world benefit for patients, supported by the world-leading discovery, experimental medicine and clinical trials infrastructure here in Oxford. I look forward to building on the legacy of this role and to continuing close collaboration with colleagues across NDORMS and the Kennedy Institute to deliver transformative impact for our patients.’
Established in 2001 through an endowment from the late Norman Collisson, the Norman Collisson Professorship is a statutory chair based within NDORMS and associated with St Peter’s College. The post provides an outstanding platform for leading and developing clinical academic rheumatology in Oxford.